The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma-Reference-Cited by-同舟云学术

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

Published:2018-01-22 Issue:14 Volume:37 Page:1830-1844
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Esteve-Arenys A.,Valero J. G.,Chamorro-Jorganes A.,Gonzalez D.,Rodriguez V.,Dlouhy I.,Salaverria I.,Campo E.^ORCID,Colomer D.,Martinez A.,Rymkiewicz G.,Pérez-Galán P.,Lopez-Guillermo A.,Roué G.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-017-0111-1.pdf

Reference46 articles.

1. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood. 2011;117:2319–31.

2. Drexler HG, Eberth S, Nagel S, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas. Leuk Lymphoma. 2016;57:1015–20.

3. Anderson MA, Tsui A, Wall M, Huang DCS, Roberts AW, Current challenges and novel treatment strategies in double hit lymphomas. Ther Adv Hematol. 2016;7:52–64.

4. Li S, Lin P, Young KH, Kanagal-Shamanna R, Yin CC, Medeiros LJ, MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol. 2013;20:315–26.

5. Turakhia SK, Hill BT, Dufresne SD, Nakashima MO, Cotta CV, Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics. Am J Clin Pathol. 2014;142:339–46.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC;Cell Communication and Signaling;2024-08-27

2. BET inhibition revealed varying MYC addiction mechanisms independent of gene alterations in aggressive B-cell lymphomas.;2024-07-22

3. Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma;Cancers;2024-06-03

4. Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers;npj Precision Oncology;2024-05-31

5. Discovery and optimization of (2-naphthylthio)acetic acid derivative as selective Bfl-1 inhibitor;Bioorganic & Medicinal Chemistry Letters;2024-03